Table 1. Characteristics of studies describing plasma and memory B cell kinetics following immunization with glycoconjugate vaccines.

Study reference	Age (y)	Number of samples per study time point*	Vaccine	Carrier protein	Number of priming doses [time since last vaccination]	Study time points (days)
Plasma cells
Kelly et al.7	13–15	3–34	MenCCV	CRM197	1 [2–3 y]	0, 3, 4, 5, 6, 7, 8, 9, 10, 12, 28
Clutterbuck et al.6	28–44	6	PCV-7†	CRM197	1 [1 y]	0, 6, 7, 15
Blanchard Rohner et al.5	1	5–26	MenCCV	CRM197	3 [8 mo]	0, 2, 4, 6, 8, 9, 30
Kelly et al.8	0.17	33	MenCCV	CRM197	-	4, 6, 8, 10, 12, 14, 16, 30
Kelly et al.8	0.33	29	MenCCV	CRM197	2 [1 mo]	4, 6, 8, 10, 12, 14, 16
Memory B cells
Kelly et al.7	13–15	3–40	MenCCV	CRM197	1 [2–3 y]	0, 3, 4, 5, 6, 7, 28, 365
Clutterbuck et al.6	28–44	6	PCV-7†	CRM197	1 [1 y]	0, 6, 7, 15, 28
Blanchard Rohner et al.5	1	4–28	MenCCV	CRM197	3 [8 mo]	0, 2, 4, 6, 8, 9, 30
Kelly et al.8	0.17	31	MenCCV	CRM197	-	4, 6, 8, 10, 12, 14, 16, 30
Kelly et al.8	0.33	17	MenCCV	CRM197	2 [1 mo]	4, 6, 8, 12, 14, 16, 30
Perrett et al.9	7	52	MenCCV	TT	3 [6 y]	0, 7, 28, 365
Perrett et al.9	8	25	MenCCV	TT	2 [6 y]	0, 28, 365
Perrett et al.9	8.3	53	MenCCV	TT	1 [6 y]	0, 7, 28, 365
Perrett et al.9	9.3	30	MenCCV	TT	1 [6 y]	0, 28, 365
Perrett et al.9	10.3	27	MenCCV	TT	1 [6 y]	0, 28, 365
Perrett et al.9	11.3	27	MenCCV	TT	1 [6 y]	0, 28, 365
Perrett et al.9	12.1	29	MenCCV	TT	1 [6 y]	0, 7, 28, 365

^*Number of samples between study time points may differ markedly and the range is given if known, otherwise the total number of samples is shown; †Values from serotype 4 were used to describe plasma and memory B cell kinetics; CRM₁₉₇, cross-reactive material (non- toxic recombinant form of diphtheria toxin); MenCCV, meningococcal serogroup C conjugate vaccine; PCV-7, 7-valent pneumococcal conjugate vaccine; TT, tetanus toxoid.